AMPY - PRISM Mid-Day Movers: Strategic Deals in Energy and Pharma Contrast Broader Market Cooldown
2025-04-28 14:00:33 ET
Plug Power Soars 32% on New $525M Credit Facility and Positive Preliminary Q1 Results
Plug Power Inc. (NASDAQ: PLUG ) surged 32.45% midday to lead the PRISM Emerging New Energy Index after announcing a $525 million secured credit facility with Yorkville Advisors and strong preliminary Q1 2025 results . The new financing agreement includes an initial $210 million tranche, which will help retire existing convertible debt and significantly reduce potential dilution. Management emphasized that Plug has no intention of raising additional equity in 2025.
Plug expects Q1 revenue between $130 million and $134 million, with Q2 revenue guidance in the range of $140 million to $180 million. Additionally, the company reported increased progress on operational efficiencies, projecting over $200 million in annual cost savings following restructuring efforts launched earlier this year. Plug also announced the successful completion of its new 15TPD hydrogen production plant in Louisiana, positioning it to serve major customers including Amazon and Walmart.
Galmed Pharmaceuticals Rallies 19% on Semaglutide Sublingual Formulation Licensing Deal
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD ) jumped 18.79%, helping lift the PRISM Emerging Pharmaceuticals Index , after announcing a signed term sheet to license and develop a novel sublingual formulation of Semaglutide . The innovative drug delivery system uses a proprietary Self-Emulsifying Drug Delivery System (SEDDS) in orally dispersible films, designed to bypass the gastrointestinal tract and deliver Semaglutide directly through oral mucous membranes.
This technology could offer a compelling alternative to current injectable (Ozempic(R), Wegovy(R)) and oral (Rybelsus(R)) forms, with potential for improved patient compliance and fewer side effects. Semaglutide or GLP-1, is projected to drive over $120 billion in global market sales for obesity and diabetes by 2030, according to Jefferies, making Galmed's licensing opportunity particularly timely.
CEO Allen Baharaff commented that he believes the proposed transmucosal administration route could enhance bioavailability, lower required dosing, and increase patient adherence.
Other PRISM Mid-Day Movers:
- iBio, Inc. (NASDQ : IBIO ) up 25.14%
- Brainstorm Cell Therapeutics Inc. (BCLI: BCLI ) up 19.28%
- Amplify Energy Corp. (NYSE: AMPY ) up 18.66%
The post PRISM Mid-Day Movers: Strategic Deals in Energy and Pharma Contrast Broader Market Cooldown appeared first on PRISM MarketView .
COMTEX_465005673/2927/2025-04-28T13:00:33